REDWOOD CITY, Calif.,
Feb. 16, 2018 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a
specialty pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
moderate-to-severe acute pain, today announced that Vincent J. Angotti, Chief Executive Officer,
will be presenting at the 2018 RBC Capital Markets Global
Healthcare Conference.
Details of the event are as follows:
2018 RBC Capital Markets Global Healthcare Conference
Date: Wednesday, February 21,
2018
Location: Lotte New York Palace Hotel, New York
Presentation Time: 8:30am ET, 5:30am
PT
Presentations will be webcast live and can be accessed through
the Investors page at www.acelrx.com. For those not available to
listen to the live broadcast, a replay will be archived for 90 days
and available through the Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for the treatment of moderate-to-severe acute pain. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
company has two product candidates including DSUVIA™ (sufentanil
sublingual tablet, 30 mcg), known as DZUVEO outside the United States, with a proposed indication
for the treatment of moderate-to-severe acute pain in medically
supervised settings, and ZALVISO® (sufentanil sublingual tablet
system, SST system, 15 microgram) being developed as an
innovatively designed patient-controlled analgesia (PCA) system for
reduction of moderate-to-severe acute pain in medically supervised
settings.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-2018-rbc-capital-markets-global-healthcare-conference-300599982.html
SOURCE AcelRx Pharmaceuticals, Inc.